Navigation Links
deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes

New risk variants published today will also be folded into deCODEme(TM)

REYKJAVIK, Iceland, Feb. 10 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced the launch of deCODE PrCa(TM), a reference laboratory test for common, single-letter variations in the human genome (SNPs) that the company has associated with increased risk of prostate cancer. deCODE believes the test will be useful for better predicting risk of prostate cancer, helping to optimize both screening and treatment. deCODE PrCa(TM) detects a total of six previously discovered SNPs that have been confirmed in many populations, as well as two SNPs on chromosomes X and 2 that are reported by deCODE scientists in a paper published today in the online edition of Nature Genetics. Although most of the variants individually confer moderate risk, they are common and some are linked to more than less aggressive disease. Consequently, a substantial proportion of men have many risk variants that together confer clinically significant risk. Because of these variants, 10% of men are at twice the risk and 1% of men are at three times the risk of the disease in the general population.

"Through deCODE PrCa(TM), we are bringing together in one tool all of the major genetic risk factors for prostate cancer that we have discovered over the past eighteen months. We believe that this is a test with significant clinical utility for improving and personalizing the screening and treatment of one of the most common cancers. At the same time, we will integrate today's discovery into the prostate cancer module in our personal genome analysis service deCODEme(TM), enabling our subscribers to stay abreast of how the latest discoveries in human genetics may relate to their genome," said Kari Stefansson, CEO of deCODE.

Today's discovery is a result of the genome-wide analysis of over 300,000 SNPs in 23,000 Icelanders in deCODE's prostate cancer studies, a finding subsequently replicated in a total of over 15,500 individuals from seven different cohorts from Europe and the United States. One of the SNPs is located on the X chromosome and the other SNP is located on chromosome 2p15 and is associated with a more aggressive form of prostate cancer. The paper, 'Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer,' can be found at deCODE PrCa(TM) is the latest in a series of reference laboratory DNA-based tests for assessing risk of and improving prevention and treatment for common diseases.

deCODE gratefully acknowledges the participation of the Icelandic patients and control subjects in its prostate cancer programs, as well as the patients and researchers from 15 academic medical centers in Europe and the United States who took part in the replication of the discovery published today.

How to order deCODE PrCa(TM)

deCODE PrCa(TM) is performed in deCODE's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory, and must be authorized by a qualified physician. If you are an individual who would like more information on deCODE PrCa(TM) to discuss with your doctor, or a physician interested in learning

more about deCODE PrCa(TM) for your patients, please visit us at

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-certified laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; and deCODE PrCa(TM) for prostate cancer. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at; on our diagnostics website at; and, for our pioneering personal genome analysis service, at

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


deCODE genetics

Berglind Olafsdottir Edward Farmer Joy Bessenger

+354 664 2393 +1 212 343 2819 +1 212 481 3891

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
2. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
5. Hospital Launches Landmark Emergency Medicine Project
6. Watson Launches Generic Biaxin(R) XL
7. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
8. APIC Launches Targeting Zero Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS
9. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
10. Launches STD Social Networking Site Balancing Dating with Online Support Features
11. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
Post Your Comments:
(Date:11/24/2015)... 2015  DILON Diagnostics and GE Healthcare are pleased ... DILON to distribute GE,s Discovery NM750b Molecular Breast Imaging ... this distribution agreement will provide Dilon,s experienced distribution network ... and is considered an initial step in an ongoing ... clinicians and their patients. --> ...
(Date:11/24/2015)... November 24, 2015 Sectra (STO: ... has entered into a multi-year agreement to deploy ... investment will provide the Breast Center a future-proof platform ... (STO: SECT B) announces that Breast Center of ... deploy Breast Imaging PACS in its two freestanding imaging ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/25/2015)... WASHINGTON, D.C. (PRWEB) , ... November 25, 2015 , ... ... driving fatalities on our nation’s roadways has dropped below 10,000 for the first time ... to 10,076 in 2013. , According to data released by the National Highway Traffic ...
(Date:11/25/2015)... ... November 25, 2015 , ... An ... is resulting in a way for homeless people to have a more dignified ... a new initiative whereby they are repurposing plastic bags into sleeping mats for ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... offering lower prices in an early celebration of the early holiday shopping season. ... of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a ... Dr. Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in ... and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the ...
(Date:11/24/2015)... ... 24, 2015 , ... DMG Productions announced that they will feature Aphria, Inc., ... via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is a publicly ... of producing and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations ...
Breaking Medicine News(10 mins):